GH Guardant Health
- 17.910
- +0.560+3.23%
Guardant Health News
Guardant Health Coverage Assumed by Craig-Hallum at Buy
Guardant Health Coverage Assumed by Craig-Hallum at Buy
Craig-Hallum Assumes Guardant Health at Buy, Announces Price Target of $28
Craig-Hallum analyst Alex Nowark assumes Guardant Health (NASDAQ:GH) with a Buy rating and announces Price Target of $28.
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
Health care stocks rose Monday afternoon with both the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each adding 1%. The iShares Biotechnology ETF (IBB) climbed 1.7%. In cor
FDA Advisory Panel Review of Guardant Health's Shield Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices Advisory Committee is scheduled
Guardant Health to Report First Quarter 2024 Financial Results on May 9, 2024
Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024. Company management will
Guardant Health Is Maintained at Buy by Goldman Sachs
Guardant Health Is Maintained at Buy by Goldman Sachs
Goldman Sachs Maintains Buy on Guardant Health, Lowers Price Target to $28
Goldman Sachs analyst Matthew Sykes maintains Guardant Health with a Buy and lowers the price target from $32 to $28.
Analyst Expectations For Guardant Health's Future
During the last three months, 5 analysts shared their evaluations of Guardant Health (NASDAQ:GH), revealing diverse outlooks from bullish to bearish.The following table encapsulates their recent ratin
Guggenheim Reiterates Neutral on Guardant Health
Guggenheim analyst Subbu Nambi reiterates Guardant Health with a Neutral.
Guardant Health Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/05/2024 — Guggenheim Reiterates → Neutral 02/26/2024 64.52% Piper Sandler $40 → $30 Maintains Overweig
Guardant Health to Present Data Highlighting Application of Epigenomics to Advance Precision Oncology at 2024 AACR Annual Meeting
New research demonstrates value of epigenomic analysis and methylation sequencing with Guardant liquid biopsy portfolio across continuum of cancer care New data show strong performance of Guardant Reveal in
20 Foods To Reduce Cancer Risk
Is There An Opportunity With Guardant Health, Inc.'s (NASDAQ:GH) 47% Undervaluation?
Key Insights Guardant Health's estimated fair value is US$39.28 based on 2 Stage Free Cash Flow to Equity Guardant Health's US$20.63 share price signals that it might be 47% undervalued Analyst p
Guardant Health Up Nearly 11%, on Pace for Largest Percent Increase Since May 2023 -- Data Talk
Guardant Health, Inc. (GH) is currently at $19.93, up $1.97 or 10.97% --Would be highest close since Feb. 26, 2024, when it closed at $20.14 --On pace for largest percent increase since May 10, 2023
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corporation (NYSE:REX) rose sharply during Thursday's session following upbeat quar
Guardant Health Revises Co-CEOs' Compensation and Incentives
32 "Breakthroughs" Stocks by BofA - Part 2
Insiders Buying Advance Auto Parts And 2 Other Stocks
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the st
Guardant Health(GH.US) Officer Buys US$38,962.72 in Common Stocks
$Guardant Health(GH.US)$ Officer Kalia Kumud purchased 2,187 shares of Common Stocks on Mar 18, 2024 at an average price of $17.8156 for a total value of $38,962.72.Source: Announcement What is statem
Buy Rating Affirmed for Guardant Health Amid Strong Shield Test Prospects and Positive ECLIPSE Study Results
Analysis
Price Target
No Data
